Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
published in: Clinical Cancer Research
date of publication: 2005-09-01
language: English
main subject: chemotherapy, angiogenesis inhibitor
Cites articles
There is nothing here
Article - wd:Q40372701